# ENCOrafenib With Binimetinib in bRAF NSCLC

> **NCT04526782** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 119 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- BRAF V600E

## Interventions

- **DRUG:** Encorafenib 75 MG
- **DRUG:** Binimetinib 15 MG

## Key facts

- **NCT ID:** NCT04526782
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-19
- **Primary completion:** 2025-07-16
- **Final completion:** 2026-03
- **Target enrollment:** 119 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526782, "ENCOrafenib With Binimetinib in bRAF NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04526782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*